Replies to post #80005 on Ayala Pharmaceuticals Inc (ADXS)

[jckrdu]

Now below $1 pre-market. Not good.

IMO, in addition to the offering with warrants, the market is spooked by the potential wind-down costs alluded to in the prospectus. Market may need guidance on those expected costs during conf call (if AXAL/Cervical is wound down) before any type of recovery is possible. It could be that KB plans to spend $5Mish to wind down AXAL/Cervical, versus spending another $15Mish over the next 2 years on a program in a limited market with an uncertain future.